NCT06352684 is a clinical trial of CadAI-B for Breast in Breast Cancer, sponsored by BeamWorks Inc..

Who is sponsoring NCT06352684?

NCT06352684 is sponsored by BeamWorks Inc..

What drugs are being tested in NCT06352684?

Interventions in NCT06352684: CadAI-B for Breast.

What condition does NCT06352684 study?

NCT06352684 studies Breast Cancer.

Is NCT06352684 still recruiting?

NCT06352684 is currently active, enrolled. Last updated 8 April 2024.

Last reviewed 2024-04-08 · How we verify

NCT06352684

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Multi-Reader Multi-Case, Retrospective Study to Evaluate Effectiveness of CadAI-B for Breast

Active, enrolled Last updated 8 April 2024

What this trial tests

trial testing CadAI-B for Breast in Breast Cancer in 1,000 participants. Participants enrolled and being followed up; not accepting new ones.

Timeline

24 November 2023

Primary endpoint
14 January 2025

14 January 2025

Quick facts

Lead sponsor	BeamWorks Inc.
Status	Active, enrolled
Study type	OBSERVATIONAL
Enrollment	1,000
Start date	24 November 2023
Primary completion	14 January 2025
Estimated completion	14 January 2025
Sites	1 location across South Korea

Drugs / interventions tested

CadAI-B for Breast

Conditions studied

Breast Cancer — all drugs for Breast Cancer →

Sponsor

BeamWorks Inc.

Who can join

19 and older, female only, with Breast Cancer. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The purpose of this study is to evaluate the effectiveness of lesion detection and diagnosis-aiding software (CadAI-B for Breast) during ultrasound (US) examination

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other recruiting trials for Breast Cancer

Currently open trials in the same condition.

NCT06148038 — CBD for Breast Cancer Primary Tumors · Phase 1 · recruiting
NCT07405801 — A Phase II Study Evaluating the Efficacy and Safety of Inavolisib Plus Ribociclib Plus Fulvestrant Versus Placebo Plus R · Phase 2 · recruiting
NCT07285993 — Detection and Outcomes in Metastatic Invasive Lobular Breast Cancer Through Novel F-18 FAP PET · Phase 2 · recruiting
NCT07510698 — Same-Day Awake Mastectomy With Immediate Breast Reconstruction for Patients With Breast Cancer · NA · recruiting
NCT06768931 — Biolosion Combined Standard Neoadjuvant Therapy to Treat Triple-negative Breast Cancer · Phase 2 · recruiting

Other BeamWorks Inc. trials

Trials by the same sponsor.

NCT07287111 — Effectiveness of CadAI-B Dx for Decision Support in Breast Ultrasound · NA · completed

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT06352684 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by BeamWorks Inc.
Last refreshed: 8 April 2024

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06352684.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing